Relief Therapeutics Holding AG (RLFTF)
Chart Events
Performance Outlook
| Previous Close | 0.0360 |
| Open | 0.0350 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0340 - 0.0380 |
| 52 Week Range | 0.0240 - 0.2150 |
| Volume | |
| Avg. Volume | 2,630,724 |
| Market Cap | 149.84M |
| Beta (5Y Monthly) | -17.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RLFTF
Related Research
- RELIEF THERAPEUTICS HOLDING AGAnalyst Report: Dell Technologies Inc.Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It is focused on premium personal computers and enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell is vertically-integrated but has a robust ecosystem of component and assembly partners, and also relies heavily on channel partners to fulfill its sales.RatingFair ValueEconomic Moat7 days agoMorningstar
- ACCESSWIRE
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced today the appointment of David McCullough as Senior Director and Head of U.S. Market Access, effective August 22 nd . In this newly created position, reporting to Anthony Kim, Senior Vice President and Head of U.S.
- GlobeNewswire
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approvalGENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), and its collaboration partner, Acer Therapeutics Inc. (Nasdaq: ACER) (Acer), today announced that the European Commission has granted orphan medicinal product designation in the EU to ACER-001 (sodium phenylbutyrate) for the potential treatment
- ACCESSWIRE
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)
RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced today promising three-month stability data on a new formulation of RLF-100® (aviptadil).
